We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes Streeting announced the five-year real-world study on Monday. It aims to ...
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.